CML Psychiatry - Volume 22 Issue 2 - Treatment Approaches to ... | cml icd 10[/caption]
cml icd 10
Wu EQ; Guerin A; Yu AP; Bollu VK; Guo A; Griffin JD
OBJECTIVE: To analyze healthcare ability utilization, costs, and analysis adherence associated with dasatinib against nilotinib analysis as second-line therapies in abiding myeloid leukemia (CML) patients.
METHODS: Two ample attendant claims databases (01/1999-06/2009) were accumulated to analyze CML patients (ICD-9 cipher 205.1x) who accustomed one or added prescriptions of dasatinib or nilotinib. Advised patients had connected acceptance ≥ 1 ages above-mentioned to and afterwards the basis date, authentic as the aboriginal decree for dasatinib or nilotinib. Patients were followed for up to 6 months from the basis date to the ancient of the abortion of healthcare plan acceptance or end of abstracts availability. Patients with cartilage bottom or axis corpuscle displace during the abstraction aeon were excluded. Poisson corruption models were acclimated to analyze healthcare ability appliance amid the two groups. Results were appear as accident amount ratios (IRR). Healthcare amount differences were estimated for anniversary amount basic application ambiguous beeline models or two-part models. Analysis adherence was abstinent by the admeasurement of canicule covered (PDC) and compared application ambiguous beeline models. Multivariate regressions were acclimated to ascendancy for abeyant abashing factors.
RESULTS: A absolute of 521 CML patients accepting second-line tyrosine kinase inhibitors (TKI) (452 dasatinib and 69 nilotinib) were studied. During the abstraction period, dasatinib patients were estimated to accept added than alert as abounding inpatient canicule (IRR = 2.44; p < 0.001) and about bifold the cardinal of inpatient admissions (IRR = 1.99; p = 0.047) compared to nilotinib patients. Over the aftereffect period, dasatinib patients incurred $8828 added in absolute medical account costs (p < 0.001); amount differences were mainly apprenticed by an adapted inpatient amount aberration of $8520 (p = 0.003). Dasatinib patients were beneath adherent, with a PDC amount about 13% lower compared to nilotinib patients (p = 0.009).
CONCLUSIONS: Among CML patients advised with second-line TKIs, nilotinib patients were added adherent and accomplished lower healthcare ability utilization, consistent in medical account amount accumulation compared to dasatinib patients.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
[caption id="" align="aligncenter" width="1200"]
ICD10 code of Chronic myelogenous leukemia (CML) and ICD9 code | cml icd 10[/caption]
[caption id="" align="aligncenter" width="236"]
ICD-10-CM Mappings 2017: Linking ICD-9-CM to All Valid ICD-10-CM ... | cml icd 10[/caption]
[caption id="" align="aligncenter" width="260"]
Pediatric ICD-10-CM 2017: A Manual for Provider-Based Coding by ... | cml icd 10[/caption]
[caption id="" align="aligncenter" width="480"]
ICDxWalk - 2016 ICD 10 Code Search and ICD 9 Crosswalk on the App ... | cml icd 10[/caption]
[caption id="" align="aligncenter" width="220"]
Chronic myelogenous leukemia - Wikipedia | cml icd 10[/caption]
[caption id="" align="aligncenter" width="411"]
Download CPT Plus (Current Procedural Terminology (CPT) Plus ... | cml icd 10[/caption]
[caption id="" align="aligncenter" width="1024"]
WBC pathology. (Subject 11) - презентация онлайн | cml icd 10[/caption]
[caption id="" align="aligncenter" width="480"]
Chronic myelocytic leukemia | chronic myelocytic leukemia icd 10 ... | cml icd 10[/caption]
[caption id="" align="aligncenter" width="220"]
Chronic myelogenous leukemia - Wikipedia | cml icd 10[/caption]
[caption id="" align="aligncenter" width="213"]
Chronic myelogenous leukemia - Wikipedia | cml icd 10[/caption]
[caption id="" align="aligncenter" width="220"]
Chronic myelogenous leukemia - Wikipedia | cml icd 10[/caption]